A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2015-11-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether the new drug AT9283 will slow the growth of
multiple myeloma. Side effects of AT9283 will also be closely monitored.